Co-Diagnostics

The WHO's PHEIC for the Bundibugyo Ebola outbreak has shifted national stockpile priorities toward rapid, locally produced diagnostics, creating demand tailwinds. Co-Diagnostics is advancing BDBV-specific and pan‑Ebola PCR assays and leverages international joint ventures—notably CoSara in India and a Saudi facility—to enable in‑country manufacturing and deployment. CoSara may pursue a public listing and will commercialize a tuberculosis test in South Asia in Q3 2026, while the parent targets an FDA 510(k) submission for the Co-Dx PCR platform in the same quarter. Recent financing, a low float and a reverse split have driven volatility; successful regulatory clearances and early TB revenues are key de‑risking milestones for investors. » More on investing.com